News

Evommune will pay $30m upfront, consisting of $20m in cash and $10m in pre-funded warrants for common shares. Hinova is eligible to receive the remainder of the deal

The partnership will initially apply blood-based circular RNA profiling to PharmatrophiX’s LM11A-31 in Alzheimer’s, with potential expansion across its neurodegeneration pipeline. LM11A-31 is the company’s first-in-class small molecule

The pharmaceutical companies did not disclose the financial terms of the deal. Under the agreement, the companies will manage regulatory approval processes and commercial operations within their allocated

The submission has been granted Priority Review, setting a target action date of 1 May 2027 under the Prescription Drug User Fee Act (PDUFA). The regulator also indicated

The acquisition involves a total enterprise valuation in the low- to mid-triple-digit millions of Swiss francs. It would expand Lonza’s US manufacturing presence from four to nine sites

The deal for the vaccine was awarded through the UK Health Security Agency. Under the contract, the company will deliver scheduled shipments of MVA-BN across the term. The

Caused by HPV-6 and/or HPV-11 primarily, RRP is characterised by the development of wart-like growths in the respiratory tract. The DNA-based immunotherapy, generically known as doruxapapogene ralaplasmid and

This transaction would add Castle Creek’s gene-modified cell therapy candidate D-Fi to Pelthos’s dermatology portfolio. The combined company would operate as Pelthos Therapeutics and continue trading on the

Set across a 6.5-acre site, the facility functions as the company’s sole distribution centre in the US. A workforce of 45 members handles administration, quality control, and general